BCMA Lentivirus

Catalog #
78714
$795 *
Size: 500 µl x 2
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The BCMA Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human BCMA (NM_ 001192) driven by a CMV promoter and a G418 selection marker (Figure 1).

Figure 1: Schematic of the lenti-vector used to generate the BCMA Lentivirus

Synonyms
Tumor necrosis factor receptor superfamily member 17, B-cell maturation protein, CD269, TNFRSF17, BCM, BCMA
Product Info
Storage and Usage
Citations
Supplied As
Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Formulation

The lentivirus particles were produced from HEK293T cells. They are supplied in cell culture medium containing 90% DMEM + 10% FBS.

UniProt #
Q02223
Background

B-cell maturation antigen (BCMA, also known as CD269 or tumor necrosis factor receptor superfamily member 17, TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CAR T cells targeting BCMA have clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.